Chronic Airway Therapeutics

Chronic Airway Therapeutics is a clinical-stage biotechnology company dedicated to the development of treatments for chronic inflammatory respiratory conditions. The company's primary focus is the development of BNC210, a negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor (α7 nAChR). By targeting this receptor, the company aims to modulate the cholinergic anti-inflammatory pathway to treat diseases such as asthma and chronic obstructive pulmonary disease (COPD). Chronic Airway Therapeutics holds an exclusive license for the respiratory applications of BNC210 from Bionomics Limited. The company was founded by industry veterans to repurpose this established clinical asset for high-need pulmonary indications, leveraging its known safety profile from previous trials in central nervous system disorders.